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LIGHT, a New Member of the TNF Superfamily,
and Lymphotoxin a Are Ligands
for Herpesvirus Entry Mediator
with a cysteine-rich extracellular domain that exhibits
significant homology with receptors for the tumor necro-
sis factor (TNF)±related cytokines (Smith et al., 1994;
Ware et al., 1995). Antibodies to HVEM inhibit HSV infec-
tion of activated T lymphocytes but not of some other
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The TNF-related cytokine-receptor systems haveHuman Genome Sciences
emerged as regulators of the afferent and effectorRockville, Maryland 20850
phases of the immune response (Smith et al., 1994; Tra-
cey and Cerami, 1994) and of elements involved during
development of lymphoid organs (Matsumoto et al.,Summary
1997b). TNF and lymphotoxin a (LTa) are compact tri-
mers assembled from subunits that have an anti-parallelHerpes simplex virus (HSV) 1 and 2 infect activated
b-sandwich topology, a feature that defines this proteinT lymphocytes by attachment of the HSV envelope
family (Eck and Sprang, 1989; Jones et al., 1989). Theglycoprotein D (gD) to the cellular herpesvirus entry
binding site for elongated cell surface receptors lies atmediator (HVEM), an orphan member of the tumor
the interface between adjacent subunits of the trimernecrosis factor receptor superfamily. Here, we dem-
(Banner et al., 1993). Ligand binding initiates cellularonstrate that HVEM binds two cellular ligands, se-
responses by clustering receptors that, in turn, activatecreted lymphotoxin a (LTa) and LIGHT, a new member
distinct signaling pathways involved in cell death or sur-of the TNF superfamily. LIGHT is a 29 kDa type II trans-
vival and differentiation. The genes for TNF, LTa, andmembrane protein produced by activated T cells that
LTb are tightly linked within the major histocompatibilityalso engages the receptor for the LTab heterotrimer
complex (MHC) onchromosome 6 (Browning et al., 1993)but does not form complexes with either LTa or LTb.
or chromosome 17 in the mouse (Lawton et al., 1995),
HSV1 gD inhibits the interaction of HVEM with LIGHT,
although the genes for other ligands in this superfamily
and LIGHT and gD interfere with HVEM-dependent cell
are dispersed across the genome. TNF, like most of its
entry by HSV1. This characterizes herpesvirus gD as relatives, is a type II transmembrane protein (Pennica
a membrane-bound viokine and establishes LIGHT- et al., 1984) that is released from the cell surface by
HVEM as integral components of the lymphotoxin cy- proteolysis (Black et al., 1997). The exception is LTa,
tokine-receptor system.
which lacks a transmembrane domain and is exclusively
secreted as a homotrimer (Gray et al., 1984). However,
Introduction when expressed as a surface protein, LTa associates
with LTb (Androlewicz et al.,1992; Browning et al., 1993),
Herpes simplex virus (HSV) 1 and 2 cause recurrent a type II transmembrane glycoprotein, as heterotrimers
infections that range in severity from benign to serious. of a1b2 and a2b1 subunit ratios (Androlewicz et al.,
HSV emerges from latency in neurons to infect the skin 1992; Browning et al., 1996).
and other tissues in thepresence of a competent cellular Lymphotoxins and TNF exhibit relatively complex re-
immune system. The virus initiates infection by binding ceptor-binding patterns whencompared to the monoga-
cell surface glycosaminoglycans and cellular proteins mous pairing of the other related ligand±receptor sys-
(Spear, 1993). Recently, a cellular HSV entry mediator tems. LTa and TNF both bind and signal through two
(HVEM) was identified by expression cloning (Montgom- receptors, the 55±60 kDa TNF receptor (TNFR60; CD120a
ery et al., 1996). HVEM is a type I transmembrane protein or type 1) (Loetscher et al., 1990; Schall et al., 1990) and
the 75±80 kDa TNFR (TNFR80; CD120b or type 2) (Smith
et al., 1990). By contrast, the surface LTa1b2 complex7 To whom correspondence should be addressed (e-mail: carl_ware@
is recognized specifically by the LTb receptor (LTbR)liai.org).
8 These authors made equal contributions. (Crowe et al., 1994b), which does not bind either LTa
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or TNF (Crowe et al., 1994b), although both TNFRs bind
the LTa2b1 heterotrimer (Crowe et al., 1994b; Browning
et al., 1995), a ligand bound weakly by the LTbR. Al-
though this apparent complexity of receptor specificity
suggests functional redundancy, deletions of LTa, LTb,
and TNF genes in mice have revealed specific roles for
each ligand in development and function of the immune
system. LTa (De Togni et al., 1994; Banks et al., 1995)
and LTb (Alimzhanov et al., 1997; Koni et al., 1997)
knockout mice develop without lymph nodes and Pey-
er's patches and fail to form germinal centers necessary
for antibody production to T cell±dependent antigens
(Matsumoto et al., 1996b; Fu et al., 1997). TNF and
TNFR60 knockout mice have normal lymph nodes but
fail to form germinal centers (Pasparakis et al., 1997).
Lymphoid organogenesis is largely attributed to signal-
ing by LTa1b2 complex through the LTbR (Ettinger et
al., 1996; Rennert et al., 1996), although differences in
the phenotypes of the LTb and LTa knockout mice have
suggested the possibility of another receptor(s) involved
in these developmental processes (Koni et al., 1997).
Here, we demonstrate that HVEM binds two ligands:
LTa and a novel membrane protein whose sequence
identifies it as a new member of the TNF superfamily.
The new cytokine, termed LIGHT, is homologous to
lymphotoxins, exhibits inducible expression, and com-
petes with HSV glycoprotein D for HVEM, a receptor
expressed by T lymphocytes. Identification of the cellu-
lar ligands for HVEM provides an essential step forward
in understanding the strategies used by herpesvirus to
Figure 1. HVEM Recognizes a Membrane-Bound Ligand on Acti-evade the immune system.
vated T Cells
(A) Expression of an HVEM ligand by activated II-23 T hybridoma
cells. (Top) II-23 cells were activated for 4 hr at 378C with phorbolResults ester (100 ng/ml) or (bottom) PMA (100 ng/ml) and ionomycin (1 mg/
ml). Cells were incubatedfor 30 min at 48C with HVEM:Fc, mLTbR:Fc,
Ligand Specificity of HVEM or human IgG at 5 mg/ml and then stained with goat anti-huIgG-PE.
Each histogram represents 104 events.Activation of T cells results in transient expression of
(B) HVEM:Fc binds activated T cells from human peripheral blood.several TNF-related ligands on the cell surface (Ware et
Peripheral blood mononuclear cells were activated with anti-CD3al., 1995). To detect a ligand(s) for HVEM, a surrogate
for 5 days in medium with IL-2. Cells were restimulated with PMA
receptor was constructed with the extracellular domain or PMA and ionomycin (Iono) for 4 hr and then dual stained with
of HVEM and the Fc region of human IgG (HVEM:Fc). FITC-CD4 or FITC-CD8, and HVEM:Fc detected with goat anti-
Activation of the CD41 II-23 T cell hybridoma with a huIgG-PE as described above.
(C) HVEM:Fc binding is competed by LTbR:Fc. (Top) activated II-23combination of the calcium ionophore, ionomycin, and
cells (PMA and ionomycin as described in [A]) were preincubatedphorbol myristate acetate (PMA) but not with PMA alone
with mLTbR:Fc or TNFR60:Fc (100 mg/ml) for 30 min at 48C. HVEM:Fcinduced specific staining with HVEM:Fc (Figure 1A). Ac-
(rabbit) (2 mg/ml) was then added, incubated for 30 min, and thetivated CD41 and CD81 subsets of T lymphocytes de-
cells stained with goat anti-rabbit IgG-PE. Rabbit IgG was used to
rived from human peripheral blood (Figure 1B) stained determine background staining. (Bottom) dose-dependent inhibition
with HVEM:Fc, indicating that the putative ligand is ex- of HVEM:Fc binding by LTbR:Fc. Binding of HVEM:Fc to activated
II-23 cells was competed with graded concentrations of mLTbR:Fc,pressed by transformed and normal cells. PMA alone
TNFR60, Fas:Fc, or IgG as described above.induces the expression of LTa, LTb, and TNF on the II-
(D) HVEM:Fc binding is competed by LTa homotrimer. (Top) II-2323 cell line (Ware et al., 1992). In contrast to HVEM:Fc,
cells were activated, and HVEM:Fc was preincubated with recombi-
staining of II-23 cells with LTbR:Fc increased with PMA nant LTa, LTaY108F, or LTa1b2 (100 nM) for 30 min at 48C. The
treatment but was substantially reduced (z60%) after mixture was added to activated II-23 cells and then stained with anti-
treatment with a combination of PMA and ionomycin huIgG-PE. Fluorescence staining with HVEM:Fc1LTa was equal to
background with normal IgG (data not shown). (Bottom) dose depen-(Figure 1A). After activation with PMA, II-23 cellsconcur-
dence of LTa competition for HVEM:Fc binding to activated II-23rently express membrane TNF and a small amount of
cells as determined by flow cytofluorometry.LTa2b1 complex as detected by the TNFR60:Fc (Crowe
et al., 1994b; Browning et al., 1995). The level of mem-
brane TNF also increased with the addition of ionomycin The LTbR:Fc and HVEM:Fc but not TNFR60:Fc com-
peted for the binding of HVEM:Fc (rabbit) (Figure 1C).(data not shown).
To determine whether HVEM might bind to TNF or The related receptors, Fas:Fc and TNFR80:Fc, did not
compete with HVEM:Fc (data not shown). Surprisingly,LTab complexes, LTbR:Fc and TNFR:Fc (Fc of human
IgG1) were used as competitive inhibitors of HVEM:Fc the LTa homotrimer (which binds TNFR) but not TNF or
LTa1b2 (the latter binds LTbR) strongly competed forconstructed with rabbit IgG (Montgomery et al., 1996).
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HVEM:Fc binding (Figure 1D). However, a mutant of LTa
at tyrosine 108 to phenylalanine (Y108F) that is unable
to engage TNFR (Goh et al., 1991; Williams-Abbott et
al., 1997) failed to compete for HVEM:Fc binding (Figure
1D). The binding curve for LTbR:Fc suggests the pres-
ence of high (z10 nM) and low affinity (z50±100 nM)
components, whereas the LTa competition curve showed
50% inhibition at approximately 50±80 nM. These results
indicate that the putative HVEM ligand(s) have charac-
teristics in common with the LTab heterotrimers and
LTa, but these features clearly distinguish it from
LTa1b2 and TNF. Expression of LTab heterotrimers in
insect cells using recombinant baculovirus (Williams-
Abbott et al., 1997) failed to reconstitute the membrane
HVEM ligand but did form ligands for LTbR:Fc and
TNFR:Fc (data not shown). Together, these results sug-
gest that the membrane protein recognized by HVEM:Fc
is similar to both lymphotoxins but distinct from the
knownforms of LTab. A biochemical approach was used
to investigate the structure of the HVEM:Fc-binding
protein.
II-23 cells secrete LTa after activation with PMA (Ware
et al., 1992; Crowe et al., 1994b). HVEM:Fc and TNFR60:Fc
precipitated proteins of 23±25 kDa from supernatants
of [35S]methionine- and [35S]cysteine-labeled II-23 cells
stimulated with PMA and ionomycin (Figure 2A, lanes
2±5). Secreted LTa displays a similar pattern of bands
that is heterogeneous due to glycosylation (Browning
et al., 1991). TNFR60:Fc but not HVEM:Fc also precipi-
tated a trace amount of a 17 kDa protein identical in
size to secreted TNF. LTbR:Fc, as expected, did not
bind any secreted proteins; however, proteins of 23±25 Figure 2. Biochemical Identification of HVEM Ligands
kDa (LTa) and 33 kDa (LTb) characteristic of the LTa1b2 (A) Receptor-mediated ligand precipitation with HVEM:Fc. II-23 cells
complex were precipitated from the cell-associated frac- activated for 4 hr with PMA or PMA and ionomycin (as in Figure 1)
were labeled with [35S]methionine and [35S]cysteine. The supernatanttion (lane 6) of PMA-activated cells. By contrast, when
or detergent extract was precleared with human IgG (10 mg) andthe stimulus included ionomycin and PMA, LTbR:Fc
protein G-Sepharose beads and then the indicated receptor:Fc fu-precipitated a major bandat 30 kDawith nearly complete
sion proteins (10 mg/ml) were then added to the samples and precipi-
absence of LTa and LTb (lane 7). TNFR60:Fc precipi- tated with protein G beads. Labeled proteins were resolved by SDS-
tated a 23 kDa protein identical in size to the LTa precur- polyacrylamide gel electrophoresis (PAGE) and phosphoimage
sor (lane 8), whereas HVEM:Fc precipitated both 30 kDa (pixel range 6±200). Lane 1, molecular weight markers; lanes 2±5,
culture supernatants; lanes 6±9, detergent extracts.and 23 kDa proteins (lane 9). Three different receptor
(B) Antigenic identity of HVEM ligands. Cellular extracts preparedblocking±monoclonal antibodies to LTb failed to remove
as in (A) were first precleared with 10 mg of mouse IgG (lane 1) orthe 30 kDa protein from the extract prior to the addition
the indicated monoclonal antibodies to LTa (lanes 2 and 5) or LTb
of HVEM:Fc, indicating this protein is antigenically unre- (lanes 3, 4, and 6), and then HVEM:Fc was added to precipitate
lated to LTb (Figure 2B, lanes 3, 4, and 6). However, ligands. The proteins bound to HVEM:Fc were then resolved by
anti-LTa antibodies removed the 23 kDa band from the SDS-PAGE and detected by phosphoimage.
(C) HVEM binds LTa and gD-1. HVEM:Fc, TNFR60:Fc, or LTbR:Fcextracts, indicating relatedness to LTa (lanes 2 and 5).
(10 mg) in 1 ml of 1% BSA, 0.1% NP-40, 0.15 M NaCl, Tris, (pH 7.4)The inability of LTa antibodies to simultaneously pre-
buffer was mixed with 1 mg of recombinant soluble TNF (lanes 2clear both the 30 kDa and 23 kDa bands demonstrates
and 6), LTa1b2 (lanes 3 and 8) or gD-1(D290-299t) (lane 5), or LTa
that these proteins are not associated with each other, (lanes 4 and 7), incubated for 1 hr at 48C, and then precipitated with
unlike the LTab heterotrimers that readily coimmuno- protein G beads. The bound proteins were resolved by SDS-PAGE
precipitate with antibody to either subunit (Androlewicz (12%) and stained with Coomassie blue.
et al., 1992; Browning et al., 1995). Peptide mapping
also showed a distinct pattern for the cell-associated
HVEM:Fc (Figure2C). This distinguishes the ligand spec-HVEM-binding protein when compared to LTb, indicat-
ificity of HVEM from both TNFRs and indicates HVEMing this protein is not likely to be an isoform of LTa or
binds at least two ligands, LTa and a distinct membraneLTb (data not shown). These results indicate that the
protein.membrane-associated HVEM ligand is antigenically dis-
tinct from LTa and LTb and displays receptor-binding
LIGHT, a Membrane-Anchored HVEM Ligandproperties that distinguish it from other known TNF-
To identify the membrane ligand for HVEM, severalrelated ligands.
cDNAs encoding proteins with sequence homology toThe identity of the secreted 23±25 kDa HVEM ligand
the TNF superfamily, identified by sequencing of an acti-as LTa was confirmed by the specific precipitation of
recombinant LTa but not soluble TNF or LTa1b2 by vated T cell library, were transfected into HEK293 cells
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(12%±18% identity, not shown in this alignment). Se-
quence homology is primarily limited to the residues
forming b-strand scaffold, suggesting this protein, like
LTa, CD40L, and TNF, folds into an anti-parallel b-sand-
wich structure and assembles as a trimer. Similarity of
LIGHT with the lymphotoxins outside the scaffold re-
gions is seen in the conservation of tyrosine 173 located
in the D-E loop, a contact region in LTa for TNFR60, and
as shown (Figure 1D) when mutated to phenylalanine
ablates the ability of LTa to compete with HVEM. The
single N-linked glycosylation site (N102) predicted for
this protein lies within the other major receptor-binding
loop (A-A99). These results strongly indicate this cDNA
encodes a similar, if not identical, protein to the HVEM
ligand expressed by activated T cells.
By Northern blot analysis, a 2.5 kb transcript for LIGHT
is expressed predominantly in spleen but also in brain
where a secondary transcript of 3.5 kb is seen (Figure 5).
A weak hybridization signal was detected in peripheral
lymphoid tissues and in heart, placenta, liver, lung, ap-
pendix, and kidney. The mRNA encoding LIGHT was
not detected in fetal tissues and organs or in many
endocrine glands and tumor lines of nonhemopoietic
and myeloid origin (data not shown).
HSV gD Is a Virokine
The possibility that HSV gD might function as an antago-
nist of the HVEM cellular ligands was suggested by the
binding of HSV gD-1 protein to HVEM (Whitbeck et al.,
1997; also see Figure 2C). This was formally tested usingFigure 3. Identification of the HVEM Surface Ligand
soluble forms of gD as antagonists of HVEM binding(A) HEK293 cells (106) were transfected with 5 mg LIGHT cDNA
to the surface of activated II-23 cells or HEK293 cells(pCDNA3 with CMV promoter) using the calcium phosphate method.
After 24 hr transfection, cells were harvested with 20 mM EDTA in transfected with LIGHT cDNA. Soluble gD-1(306t) and
PBS and incubated with HVEM:Fc, mLTbR:Fc, TNFR:Fc, Fas:Fc, or gD-1(D290-299t), a mutant with enhanced binding for
IgG and stained with anti-huIgG-PE. Mock-transfected cells did not HVEM (Whitbeck et al., 1997) and the ability to block
stain with any Fc fusion protein.
HSV infectivity (Nicola et al., 1996), were both effective(B) HEK293 cells transfected with LIGHT cDNA or cotransfected
at inhibiting HVEM:Fc binding to the surface of activatedwith LTa and LTb cDNAs (pCMD8 with CMV promoter) (as described
II-23 cells (Figure 6A) and LIGHT-transfected cells (Fig-above) were metabolically labeled and the extracts precipitated with
mLTbR:Fc (lanes 2 and 6), TNFR60:Fc (lanes 3 and 7), HVEM:Fc ure 6B). The effective inhibitory concentration of gD-1
(lanes 4, 5, and 8) as described above. For comparison, in lane 5, proteins correlated with their affinity for HVEM (Whit-
the HVEM:Fc precipitation was from metabolically labeled activated beck et al., 1997). The competition curve with gD-1
II-23 cells.
(D290-299t) on II-23 cells suggests the presence of high-
and low-affinity components. The biphasic curve is also
apparent with LIGHT-transfected cells, although the
and assayed for HVEM:Fc binding by flow cytometry. high affinity site is a minor component. This result sug-
Transfection of one of these cDNAs resulted in specific gests that cooperative binding interactions occur be-
staining of HEK293 cells by HVEM:Fc and LTbR:Fc but tween HVEM:Fc and the surface ligand, rather than mul-
not TNFR60:Fc or Fas:Fc (Figure 3A). A 28±29 kDa pro- tiple ligands with different affinities for HVEM:Fc. The
tein (observed as a doublet) was specifically precipi- binding of LTbR:Fc or TNFR60:Fc to PMA or PMA/iono-
tated by HVEM:Fc and LTbR:Fc but not by TNFR60:Fc mycin-activated II-23 cells was not inhibited by gD-
from extracts of metabolically labeled HEK293 cells 1(D290-299t), indicating that the binding between HVEM
transfected with this cDNA (Figure 3B). The primary and gD-1 is highly specific (data not shown).
structure of this protein predicted from the cDNA se- Human cells that express gD-1 can be resistant to
quence (Figure 4A) contains 240 amino acids with an HSV1 entry (Campadelli-Fiume et al., 1988; Johnson and
N-terminal cytosolic domain of 37 residues that pre- Spear, 1989), possibly due to receptor blockade or se-
cedes a stretch of 22 hydrophobic residues characteris- questration of the receptor inside the cell. This interfer-
tic of a type II transmembrane protein. LIGHT exhibits ence phenomenon and the results described above sug-
significant sequence homology with the C-terminal re- gested that LIGHT or gD-1, if coexpressed with HVEM,
ceptor-binding domains of LTb (34% identity), Fas Li- might interfere with HSV1 entry of cells via HVEM. To
gand (31%), 41BBL (29%), TRAIL (28%), LTa (27%), TNF test this, resistant CHO cells were cotransfected with an
(27%), and CD40L (26%) (Figure 4B). The ligands for HVEM-expressing plasmid, which confers susceptibility
to HSV1 entry, and a plasmid expressing LIGHT or gD-1,CD30, CD27, and OX-40 exhibit the weakest homology
Lymphotoxins and Herpesvirus Entry
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Figure 4. Sequence of LIGHT and Alignment with TNF Superfamily
(A) Amino-acid sequence deduced from the cDNA sequence. The asterisk (*) indicates the position of the predicted N-glycosylation site.
(B) Alignment of LIGHT with TNF-related ligands. Sequences were aligned with ClustalW (Pam250 matrix) (Macvector). This alignment excludes
ligands for CD27, CD30, and Ox-40. Asterisks, the contact residues in LTa for TNFR60; bars, the b-strands that form the scaffold in LTa as
designated by convention (Eck et al., 1992). Homology regions are boxed with identical residues shaded.
or a control plasmid. The cells were then inoculated 7). Cotransfection of HVEM with LIGHT or gD-1 but not
with control plasmid dramatically inhibited virus entry,with various concentrations of recombinant HSV1, KOS-
gL86, which expresses b-galactosidase upon viral entry, whereas LIGHT and control plasmid did not confer sus-
ceptibility. These results indicate that LIGHT as well asand enzyme levels were quantitated after 6 hr. (Figure
gD-1 can interfere with HSV1 entry via HVEM.
Discussion
The work presented here establishes HVEM and LIGHT
as integral components of the LT/TNF cytokine-receptor
system. The ligand and receptor interactions in this sys-
tem show a significant divergence in specificity, al-
though substantial overlap is evident in cognate pairing
(eg., LTa binds TNFR60, TNFR80, and HVEM). At pres-
ent, the majority of evidence indicates that each ligand±
receptor pair identified so far functions autonomously
in ligand binding and signaling activities. However, theFigure 5. Expression of LIGHT mRNA
cross-specificity of several receptors certainly suggestsNorthern blot analysis of poly(A)1 RNA (2 mg/lane) from various
that cooperative interactions could occur, and recenthuman tissues. Numbers on the left indicate the lengths of RNA
molecular size standards. RNA from spleen was used as common evidence with TNFR supports this concept (Pinckard
positive tissue for estimating variation in the hybridization signal. et al., 1997). Our results also demonstrate LIGHT is a
Tissues tested include the following: pancreas (Pa), kidney (K), skel- previously unrecognized membrane-anchored ligand
etal muscle (SM), liver (L), lung (Lu), placenta (Pl), brain (B), heart for LTbR, a finding that establishes a direct relation
(H), peripheral blood leukocytes (PBL), mucosal lining of colon (C),
between LTbR and HVEM. It is not surprising that LTbsmall intestine (SI), ovary (O), testis (T), prostate (P), thymus (Th),
and LIGHT are closely related in their primary sequence,spleen (Sp), lymph node (LN), appendix (A), bone marrow (BM), and
fetal liver (FL). suggesting a close functional link exists between these
Immunity
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Figure 7. LIGHT Interferes with HVEM-Dependent HSV1 Infection
CHO-K1 cells were cotransfected with the HVEM-expressing plas-
mid pBEC10 (Montgomery et al., 1996) and control vector pcDNA3,
gD-expressing plasmid pRE4 (Cohen et al., 1988), or LIGHT-express-
ing plasmid pcDNA3-LIGHT; or with the LIGHT-expressing plasmid
pcDNA3-LIGHT and control vector pcDNA3. Transiently transfected
cells were harvested at 24 hr and plated into 96-well dishes. After
overnight incubation, cells were challenged with KOS-gL86 at the
indicated doses. After 6 hr of infection, the activity of b-galactosi-
dase expressed from the input viral genome was quantitated. Each
point represents the mean of triplicate determinations and individual
values were within 10% of the mean. Values reported were obtained
1.5 hr after o-nitrophenyl b-D-galactopyranoside addition.
brain. Together, the structural and functional differences
between LIGHT and LTab heteromers strongly suggest
that their roles in immune physiology are distinct.
Likewise, HVEM and LTbRshare significant properties
but have distinguishing features that indicate their phys-
iologic roles are distinct. HVEM and LTbR share the
potential to activate common signaling pathways via
association with TNFR-associated factors (TRAFs), a
family of zinc RING-finger proteins involved in signaling
by several members of the TNFR superfamily. HVEM
binds TRAF2 and 5 (Marsters et al., 1997; Hsu et al.,
Figure 6. HSV1 gD Inhibits HVEM:Fc Binding to Activated II-23 Cells
1997), as does LTbR (Nakano et al., 1996), and activatesand LIGHT-Transfected HEK293 Cells
NFkB, a transcription factor involved in regulation of(A) (Top) HVEM:Fc (2 mg/ml) was preincubated for 30 min at 48C
proinflammatory and anti-apoptotic genes. LTbR in-with gD-1(306t) (250 mg/ml) or gD-1(D290-299t) (100 mg/ml) and then
duces apoptosis of an adenocarcinoma line by activat-added to PMA and ionomycin±activated II-23 cells (as in Figure 1A).
Background staining was determined with human IgG (data not ing a TRAF3-dependent pathway (VanArsdale et al.,
shown) and is equal to HVEM:Fc1gD-1(D290-299t). (Bottom) gD-1 1997). In contrast, we have not identified any cell lines
competition binding analysis. Binding of HVEM:Fc to activated II- for which HVEM antibodies trigger apoptosis, a finding
23 cells was competed with graded concentrations of gD-1(306t)
that correlates with the weak interactions betweenor gD-1(D290±299t) as indicated in Figure 1.
HVEM and TRAF3 (Marsters et al., 1997; K. D. K. and(B) (Top) HEK293 cells transfected with LIGHT cDNA were used as
C. F. W., unpublished data). The interaction betweenin (A).
LIGHT and LTbR suggests that LIGHT, in addition to
LTa1b2, may activateapoptosis via the LTbR,a possibil-
ity currently being investigated.two systems. However, these ligands differ in several
Collectively, these results indicate the physiologicimportant aspects. For instance, LTb does not form a
function(s) of the LIGHT/LTa-HVEM pathway are proba-homotrimer; instead, it assembleswith LTa into a biolog-
bly distinct from TNF/LTa-TNFR and LTa1b2/LIGHT-ically active heterotrimer (Williams-Abbott et al., 1997).
LTbR pathways. Genetic deletions of LTa or LTb genesIn contrast, LIGHT is predicted to be a homoligomer.
in mice have revealed roles for these two genes in theAlso, preliminary evidence indicates the LIGHT gene is
development of lymph nodes and Peyer's patches (Denot linked to the TNF/LT locus in the MHC (Zhai et al.,
Togni et al., 1994; Banks et al., 1995). Along with TNFunpublished data). Furthermore, LTab and LIGHT ex-
and TNFR60, LTa and LTb also control the formation ofpression on the surface of activated T cells requires
germinal centers necessary for immunoglobulin-isotypedifferent activating signals. PMA is sufficient to induce
switching during immune responses in adults (Mariatha-LTa1b2, whereas Ca ionophore with PMA is required
san et al., 1995; Matsumoto et al., 1996a, 1996b). Mostfor LIGHT and suppresses the expression of LTa1b2.
studies have pointed toward the LTa1b2 and LTbR asLIGHT and LTb mRNAs are expressed in lymphoid tis-
sues; however, LIGHT mRNA is also detected in the the critical cytokine-receptor system controlling these
Lymphotoxins and Herpesvirus Entry
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functions (Crowe et al., 1994b; Ettinger et al., 1996; Ren- mimics LIGHT, and it implicates gD-1 as a potential
modifier of HVEM-signaling activities during entry ornert et al., 1996; Koni et al., 1997). However, the pheno-
types of LTa and LTb knockout mice differ, particularly egress of HSV. Furthermore, expression of gD on the
surface of infected cells occurs well before the releasethe presence of cervical and mesenteric lymph nodes
in LTb2/2 mice (Alimzhanov et al., 1997; Koni et al., 1997). of mature virions (Spear, 1993), and such cells could
also interact with HVEM-bearing T or B cells. It remainsIn addition, organization of T and B cell compartments
in the spleen is not as severely disrupted in the LTb2/2 to be seen whether this interaction causes immune mod-
ulation of T or B cells either by free HSV virions or bymice as in the LTa2/2 mice, a finding suggesting that
another receptor may engage the LTa. Moreover, LTa infected cells bearing gD on the cell surface. Of interest
is the observation that Epstein-Barr virus (g herpesvirus)transgenic mice (presumably that overexpress secreted
LTa and not LTab complexes) grow extralymphatic modifies signal transduction by TNFR through the action
of the transforming protein LMP1. LMP1 binds memberslymph node±like structures (Picarella et al., 1992; Kratz
et al., 1996). The cross-specificity of LIGHT and LTbR of the TRAF family (Mosialos et al., 1995), activates
NFkB, and thus functions like a constitutively activatedand LTa and HVEM makes the LIGHT/LTa-HVEM path-
way a likely candidate to account for the differences receptor (VanArsdale et al., 1997). Members of the TNF
and TNFR superfamilies are targeted by a number ofobserved among the lymphotoxin transgenic and knock-
out mice. specific mechanisms (Gooding, 1992) found in a diverse
group of viruses that include poxvirus (Schreiber et al.,The unique phenotypes of the LTa and LTb knockouts
suggest that LIGHT and LTa1b2 are not redundant li- 1997), adenovirus (Shisler et al., 1997), hepatitis C virus
(Matsumoto et al., 1997a), and g herpesvirus (Bertin etgands for the LTbR. Several possibilities could account
for the distinct activities of these ligands signaling al., 1997). These examples provide compelling evidence
that counteracting immune defense strategies is essen-through the same receptor. LIGHT mRNA was not de-
tected in the embryonic tissues, raising the possibility tial for virus survival and persistence. It is enticing to
speculate that the selective pressure brought to bearthat it may not function during lymph-node genesis.
Another possibility is that these two ligands activate upon the immune system by herpesvirus has driven the
diversification of the LT ligands and their receptors, anddifferent signaling pathways by the LTbR. A potential
precedent for this is seen in the LTa2b1 heteromer that perhaps the collective onslaught of viruses has contrib-
uted to the expansion of these cytokines into its presentbinds both TNFR60 and LTbR but does not activate
these receptors in a way that mimics TNF/LTa or superfamily size. The identification of HVEM as a recep-
tor that interacts with LTa and LIGHT should assist inLTa1b2. (LTa2b1 is a minor form and a functional role,
if any, remains to be discovered.) An alternate explana- understanding the complex virus±host relationship.
tion is that HVEM and LTbR signal in a tissue-specific
Experimental Procedurescontext. The latter point is intriguing because HVEM and
LTbR have distinct tissue expression patterns: HVEM is
Cellsprominent on T and B lymphocytes (D. N. M., unpub-
The II-23 cell line (D7 subclone) is a human CD41 T cell hybridoma
lished data; Kwon et al., 1997), whereas LTbR is absent (Ware et al., 1986) and is maintained in RPMI-1640 with 10% fetal
on lymphocytes but is prominent on the stroma in the bovine serum (FBS) and antibiotics. II-23 cells were activated with
PMA (100 ng/ml) or PMA and ionomycin (1 mg/ml) for 2.5 hr, washedthymus and spleen and is expressed on a follicular den-
twice with PBS, once with cysteine-methionine±deficient RPMI, anddritic cell line (Force et al., 1996; Murphy et al., 1998).
then resuspended in this medium containing 10% dialyzed FBS,The ability of LTbR to stimulate expression of adhesion
250 mCi [35S]methionine and cysteine, and activating agents for 1.5proteins ICAM and VCAM (Hochman et al., 1996) and
hr. The supernatants were harvested, and the cells were lysed in
chemokines (Degli-Esposti et al., 1997) suggests this buffer containing 2% NP40, HEPES (pH 7.0), 20 mM EDTA, 150 mM
receptor is important for creating tissue microenviron- NaCl with leupeptin and aprotinin (at 10 mg/ml), phenylmethylsulfo-
nyl fluoride (1 mM), and iodoacetamide (20 mM). Peripheral bloodments suitable for productive T and B cell interactions.
lymphocytes were obtained from normal donors by Ficoll-HypaqueLikewise, the expression of HVEM on T and B cells
and cultured in medium supplemented with IL-2 (10 ng/ml) aftersuggests that it may also participate as a regulator of
stimulation with anti-CD3 (OKT3) or phytohemagglutinin.cellular differentiation during formation of germinal cen-
ters in peripheral lymphoid organs. Recent studies with Receptor:Fc Fusion Proteins, Antibodies, and HSV gD-1
Hox-11 knockoutmice that are asplenic, as well as alym- Construction, expression, and purification of the bivalent chimeric
phoplasia (aly) mice that lack lymph nodes, have re- proteins formed with the Fc region of human IgG1 and the ligand-
binding domains of Fas:Fc (Brunner et al., 1995), TNFR60 (Crowevealed an essential role for peripheral lymph organs in
et al., 1994a), and human LTbR:Fc (Crowe et al., 1994b) have beenanti-virus defenses (Karrer et al., 1997). Although these
previously described. The extracellular region of HVEM was gener-genes are unrelated to known members of the TNF su-
ated by polymerase chain reaction using Taq DNA polymerase±
perfamily, they provide clues that the interaction be- amplified sequences from pBEC10 DNA encoding 1-K184 using the
tween herpesvirus and the LT system is not fortuitous. forward primer 59-CGGAGATCTGAGTTCATCCTGCTAGCTGG and
Our results provide a molecular link connecting the reverse primer 59-ATAGGATCCCTTGGTCTGGTGCTGACATTCC.
The amplified HVEM product was ligated in-frame into the baculovi-envelope protein gD of HSV1 (an a herpesvirus) with
rus vector pVL1392 (Pharmingen) containing the human Fc IgG1. Athe LT cytokine-receptor system. The ability of gD-1 to
similar construct of HVEM:Fc with Fc region from rabbit IgG1 wasspecifically compete with LIGHT for binding HVEM but
produced in CHO cells, purified, and used as an immunogen to
not LTbR suggests that gD-1 may have evolved specifi- produce rabbit anti-HVEM (Montgomery et al., 1996). LTbR:Fc was
cally for the LIGHT±HVEM interaction. The ability of constructed from mouse LTbR (mLTbR) DNA fragment (Force et al.,
LIGHT to block HVEM-dependent HSV1 infection indi- 1996) by polymerase chain reaction using Taq DNA polymerase with
forward primer 59-GACGTCAGATCTTCCCACCTTTCCTCCTA-39cates that gD-1 is a membrane-anchored virokine that
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and reverse primer 59-GAACAGAGATCTCATTGCTCCTGGCTCTG-39 virus KOS-gL86. Infections and quantitation of infection using the
b-galactosidase substrate o-nitrophenyl b-D-galactopyranoside (3and encodes amino acid residues 1-Met221 of the extracellular do-
main. LTa andLTaY108F were produced in insect cells using recom- mg/ml) were performed as described previously (Montgomery et al.,
1996).binant baculovirus as described (Crowe et al., 1994a; Williams-
Abbott et al., 1997). Recombinant soluble LTa1b2 (Browning et al.,
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After stimulation, cells for flow cytometry were harvested, washed,
and incubated on ice in Hanks' balanced salt solution with 10%
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